Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675662 | 1.00 | BTN3A1 (0.45) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL723035 | 1.00 | BTN3A1 (0.45) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL22582156 | 0.90 | ALDH1A1 (0.43) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL30628342 | 0.90 | ALDH1A1 (0.43) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL12274119 | 0.90 | ALDH1A1 (0.43) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL722416 | 0.89 | KMT2A (0.41) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL789912 | 0.88 | ALDH1A1 (0.44) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL1273006 | 0.87 | BTN3A1 (0.45) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL23378011 | 0.86 | BTN3A1 (0.45) | BTN3A1ALDH1A1HSD17B10PGRGAA | |
| SCHEMBL30424106 | 0.86 | BTN3A1 (0.45) | BTN3A1ALDH1A1HSD17B10PGRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-02-03 | — | — | US | disclosed |
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | NuCana plc (GB) | 2021-06-22 | — | — | US | disclosed |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| EP-2935303-B1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | JANSSEN BIOPHARMA INC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2013092481-A1 | 2',4'-DIFLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092447-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013044030-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | BTN3A1 3601/4885ALDH1A1 1686/4885HSD17B10 969/4885 |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | BTN3A1 4601/4885ALDH1A1 4139/4885HSD17B10 4596/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885ALDH1A1 1431/4885HSD17B10 3628/4885 |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | BTN3A1 3601/4885ALDH1A1 1686/4885HSD17B10 969/4885 |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | BTN3A1 3840/4885ALDH1A1 2544/4885HSD17B10 3847/4885 |
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | PNP, MTAP, TYMP | BTN3A1 4055/4885ALDH1A1 2613/4885HSD17B10 3889/4885 |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | BTN3A1 3601/4885ALDH1A1 1686/4885HSD17B10 969/4885 |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885ALDH1A1 1431/4885HSD17B10 3628/4885 |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | BTN3A1 3191/4885ALDH1A1 2125/4885HSD17B10 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.